Skip to main content

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference

Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming trial, EBRX-101 is designed to be one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT to advance it as a therapy for addiction disorder.

In addition, Entheon is focusing on the identification, analysis and predictive use of genetics and EEG biomarkers to develop a treatment system that personalizes care through all stages of the treatment continuum. Entheon believes a comprehensive approach to treatment will significantly increase the odds of permanent recovery for those struggling to overcome addiction.

Entheon is comprised of three divisions, Entheon RX(TM), focused on the development of therapeutic drugs, using DMT as the pharmacological benchmark; Entheon ID(TM), focused on identification, analysis and predictive use of EEG biomarkers and genetics in the selection and management of drug treatment; and Entheon IQ(TM), focused on the development of treatment algorithms through the analysis of patient data.

Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada. For more information, visit the company’s website at or connect with Entheon on Twitter or LinkedIn.

To learn more about Benzinga’s Small Cap Conference, visit:

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.